跳至主要内容
临床试验/NCT07641218
NCT07641218尚未招募不适用

Pilot Clinical Investigation of the ARTUS® Artificial Urinary SPHincter (AUS) for the Treatment of Stress UrInary iNcontinence (SUI) in Women

Myopowers Medical Technologies France SAS2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2026年6月30日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
6
试验地点
2

研究概览

简要总结

The subjects will be implanted with the ARTUS® medical device and then be followed up to 2 years post-implantation, with the primary endpoints measured at 3-month post-implantation. Safety and Clinical performance outcomes will be measured for each subject at baseline (before implantation) and post-implantation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female subject over 18 years of age at the time of consent signature
  • Subject with persistent severe urinary incontinence:
  • at least 3 months after failed pelvic floor muscle training OR
  • at least 6 months after a failed surgical treatment (e.g. slings)
  • Subject with severe Stress Urinary Incontinence, defined as a mean value of 3 consecutive 24-hour Pad Weight Test > 100 grams
  • Subject willing and able to provide written informed consent and having signed the informed consent
  • Subject having understood and accepted to be unable to proceed to an MRI examination after the surgical procedure due to the non-MRI compatibility of the device
  • Subject having a life expectancy ≥ 5 years as assessed by the investigator

排除标准

  • Subject currently enrolled or plans to participate in another investigational study of a drug, biologic, or medical device from the point of enrolment through the 12 months post device activation period
  • Subject deprived of liberty by administrative or judicial decision or under legal guardianship
  • Subject who is unwilling or deemed by the investigator to be unwilling to comply with the clinical study requirements, including attending follow-up visits.
  • Subject having inadequate cognitive or capabilities to use the Artus device as assessed by the investigator
  • Pregnant subject, or subject willing to be pregnant during the study duration, or subject of child-bearing potential with non-stable medication contraception
  • Subject with urge incontinence due to hyperactive bladder not adequately controlled by drug therapy
  • Subject with overflow urinary incontinence
  • Subject with Significant Neuro-urological disorders: elevated detrusor pressure, Detrusor sphincter desinergy
  • Subject with history of pelvic radiotherapy
  • Subject with any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes
  • Subject with known allergy to any components of the device
  • Subject with history of Artificial Urinary Sphincter
  • Subject with severe congenital or acquired haemorrhagic disease, haemophilia, or another coagulopathy
  • Subject under anti-coagulation or anti-platelet medication that cannot be discontinued at least 5 days prior to surgery and restarted at least 5 days after surgery
  • Subject having a Body Mass Index (BMI) > 40
  • Subject with uncontrolled diabetes, defined as HbA1c > 9.0% within the past 6 months
  • Subject with history of urethral fistula
  • Subject with history of bladder tumor
  • Subject with severe urethral stenosis.
  • Subject with currently active infection, including urinary tract infection
  • Subject with severe renal failure or obstructive pathologies of the upper urinary tract with severe renal failure
  • Subject with congenital or acquired immunodeficiency, including those who are immunocompromised or immunosuppressed
  • Subject with post void residual volume greater than 200 mL within the past 6 months
  • Subject with history of recurrent bladder stones or history of failed bladder stone treatment within the past 12 months
  • Subject in emergency situation (caused by a sudden life threatening or other sudden serious medical condition including but not limited to heart attack, stroke, coma, epileptic seizure, heavy bleeding, severe pain, trouble breathing…)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验